ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 310 participants.
Also called NCT01228227
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 310 participants
- Sponsor
- Gennaro Sardella
- Registry
-
NCT01228227
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT01228227. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading
- Acronym
- ROMAIIReload
- Condition
- Assess the Periprocedural Myocardial Necrosis
- Intervention (Drug)
- ATORVASTATIN 80 mg
- Intervention (Drug)
- ROSUVASTATIN 40 mg
- Lead sponsor
- Gennaro Sardella
Record details
- Record id
cardio:ct-nct01228227- Content hash
3a10ba5a3baa85f9e0002a7b54f26ed29777dac6ff264af12f5f91e5e7e3e596